Drug Approval | February 26, 2022
Japan approves Keytruda plus Lenvima for two types of cancer
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
New inhalers would have near-zero Global Warming Potential propellant
US $ 555,000 invested by Wavemaker Partners in pre-seed round
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Key takeaways of Q3FY22 quarter & conference call highlights
MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Subscribe To Our Newsletter & Stay Updated
